Primary HIV Infection: Clinical Presentation, Testing, and Treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-09-07

AUTHORS

Aurélia Henn, Clara Flateau, Sébastien Gallien

ABSTRACT

Purpose of ReviewThe purpose of this review was to provide current data on clinical presentation, diagnosis, and treatment of primary HIV infection (PHI).Recent FindingsIn 65 to 95% of cases, PHI causes acute retroviral syndrome presenting with unspecific flu-like symptoms. Symptomatic PHI was associated with a faster clinical and immunological progression of HIV infection. Point-of-care tests remain less sensitive than fourth-generation immunoassays (IA) in PHI, especially after tenofovir-based prophylaxis use. Early antiretroviral treatment (ART) started during PHI prevents HIV transmission and decreases viral and immunological reservoir constitution. Recommended ART regimens in PHI are combinations of tenofovir and emtricitabine with either darunavir/ritonavir, or dolutegravir.SummaryStarting ART the earliest is highly recommended for clinical, virological, immunological, and public health benefits. Reducing HIV reservoir constitution in PHI may optimize potential opportunities for future functional cure. More... »

PAGES

37

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11908-017-0588-3

DOI

http://dx.doi.org/10.1007/s11908-017-0588-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091501707

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28884279


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Facult\u00e9 de m\u00e9decine, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France", 
          "id": "http://www.grid.ac/institutes/grid.410511.0", 
          "name": [
            "Service d\u2019immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Creteil, France", 
            "Facult\u00e9 de m\u00e9decine, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Henn", 
        "givenName": "Aur\u00e9lia", 
        "id": "sg:person.01122530351.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122530351.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Creteil, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service d\u2019immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Creteil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Flateau", 
        "givenName": "Clara", 
        "id": "sg:person.01113507765.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113507765.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Facult\u00e9 de m\u00e9decine, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France", 
          "id": "http://www.grid.ac/institutes/grid.410511.0", 
          "name": [
            "Service d\u2019immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Creteil, France", 
            "Facult\u00e9 de m\u00e9decine, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gallien", 
        "givenName": "S\u00e9bastien", 
        "id": "sg:person.01077063633.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077063633.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10461-017-1788-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085215059", 
          "https://doi.org/10.1007/s10461-017-1788-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12879-015-0892-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047706498", 
          "https://doi.org/10.1186/s12879-015-0892-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-09-07", 
    "datePublishedReg": "2017-09-07", 
    "description": "Purpose of ReviewThe purpose of this review was to provide current data on clinical presentation, diagnosis, and treatment of primary HIV infection (PHI).Recent FindingsIn 65 to 95% of cases, PHI causes acute retroviral syndrome presenting with unspecific flu-like symptoms. Symptomatic PHI was associated with a faster clinical and immunological progression of HIV infection. Point-of-care tests remain less sensitive than fourth-generation immunoassays (IA) in PHI, especially after tenofovir-based prophylaxis use. Early antiretroviral treatment (ART) started during PHI prevents HIV transmission and decreases viral and immunological reservoir constitution. Recommended ART regimens in PHI are combinations of tenofovir and emtricitabine with either darunavir/ritonavir, or dolutegravir.SummaryStarting ART the earliest is highly recommended for clinical, virological, immunological, and public health benefits. Reducing HIV reservoir constitution in PHI may optimize potential opportunities for future functional cure.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11908-017-0588-3", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021184", 
        "issn": [
          "1523-3847", 
          "1534-3146"
        ], 
        "name": "Current Infectious Disease Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "primary HIV infection", 
      "antiretroviral treatment", 
      "HIV infection", 
      "clinical presentation", 
      "symptomatic primary HIV infection", 
      "fourth-generation immunoassays", 
      "early antiretroviral treatment", 
      "Prevent HIV Transmission", 
      "darunavir/ritonavir", 
      "acute retroviral syndrome", 
      "flu-like symptoms", 
      "combination of tenofovir", 
      "public health benefits", 
      "immunological progression", 
      "prophylaxis use", 
      "functional cure", 
      "HIV transmission", 
      "ReviewThe purpose", 
      "care test", 
      "health benefits", 
      "infection", 
      "treatment", 
      "current data", 
      "presentation", 
      "immunoassay", 
      "tenofovir", 
      "emtricitabine", 
      "ritonavir", 
      "dolutegravir", 
      "syndrome", 
      "symptoms", 
      "diagnosis", 
      "progression", 
      "cure", 
      "review", 
      "potential opportunities", 
      "purpose", 
      "testing", 
      "cases", 
      "benefits", 
      "test", 
      "transmission", 
      "use", 
      "combination", 
      "data", 
      "opportunities", 
      "point", 
      "constitution"
    ], 
    "name": "Primary HIV Infection: Clinical Presentation, Testing, and Treatment", 
    "pagination": "37", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091501707"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11908-017-0588-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28884279"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11908-017-0588-3", 
      "https://app.dimensions.ai/details/publication/pub.1091501707"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_723.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11908-017-0588-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11908-017-0588-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11908-017-0588-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11908-017-0588-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11908-017-0588-3'


 

This table displays all metadata directly associated to this object as RDF triples.

139 TRIPLES      21 PREDICATES      76 URIs      65 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11908-017-0588-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1108
4 schema:author Nf804302418da4e299c257806eeeafd80
5 schema:citation sg:pub.10.1007/s10461-017-1788-4
6 sg:pub.10.1186/s12879-015-0892-1
7 schema:datePublished 2017-09-07
8 schema:datePublishedReg 2017-09-07
9 schema:description Purpose of ReviewThe purpose of this review was to provide current data on clinical presentation, diagnosis, and treatment of primary HIV infection (PHI).Recent FindingsIn 65 to 95% of cases, PHI causes acute retroviral syndrome presenting with unspecific flu-like symptoms. Symptomatic PHI was associated with a faster clinical and immunological progression of HIV infection. Point-of-care tests remain less sensitive than fourth-generation immunoassays (IA) in PHI, especially after tenofovir-based prophylaxis use. Early antiretroviral treatment (ART) started during PHI prevents HIV transmission and decreases viral and immunological reservoir constitution. Recommended ART regimens in PHI are combinations of tenofovir and emtricitabine with either darunavir/ritonavir, or dolutegravir.SummaryStarting ART the earliest is highly recommended for clinical, virological, immunological, and public health benefits. Reducing HIV reservoir constitution in PHI may optimize potential opportunities for future functional cure.
10 schema:genre article
11 schema:isAccessibleForFree false
12 schema:isPartOf N1bbbe22486804306bac9214febf6ef7b
13 Nb192e0f288e241a38f7ee299fcd00135
14 sg:journal.1021184
15 schema:keywords HIV infection
16 HIV transmission
17 Prevent HIV Transmission
18 ReviewThe purpose
19 acute retroviral syndrome
20 antiretroviral treatment
21 benefits
22 care test
23 cases
24 clinical presentation
25 combination
26 combination of tenofovir
27 constitution
28 cure
29 current data
30 darunavir/ritonavir
31 data
32 diagnosis
33 dolutegravir
34 early antiretroviral treatment
35 emtricitabine
36 flu-like symptoms
37 fourth-generation immunoassays
38 functional cure
39 health benefits
40 immunoassay
41 immunological progression
42 infection
43 opportunities
44 point
45 potential opportunities
46 presentation
47 primary HIV infection
48 progression
49 prophylaxis use
50 public health benefits
51 purpose
52 review
53 ritonavir
54 symptomatic primary HIV infection
55 symptoms
56 syndrome
57 tenofovir
58 test
59 testing
60 transmission
61 treatment
62 use
63 schema:name Primary HIV Infection: Clinical Presentation, Testing, and Treatment
64 schema:pagination 37
65 schema:productId N214ccabe5a084d04b0a095c82c578553
66 N881b9780b0dc41aca13870e8eacf1e00
67 Nb5708d34e78e4b348a155ac1736d7f83
68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091501707
69 https://doi.org/10.1007/s11908-017-0588-3
70 schema:sdDatePublished 2022-11-24T21:02
71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
72 schema:sdPublisher N88164d945b8b47e7b80d6a3a3a5e5f70
73 schema:url https://doi.org/10.1007/s11908-017-0588-3
74 sgo:license sg:explorer/license/
75 sgo:sdDataset articles
76 rdf:type schema:ScholarlyArticle
77 N1bbbe22486804306bac9214febf6ef7b schema:issueNumber 10
78 rdf:type schema:PublicationIssue
79 N214ccabe5a084d04b0a095c82c578553 schema:name pubmed_id
80 schema:value 28884279
81 rdf:type schema:PropertyValue
82 N3f8c1d801d08431fb8059824df0714ac rdf:first sg:person.01113507765.40
83 rdf:rest Nb35f2684f920474dad0532c12e5d6b50
84 N88164d945b8b47e7b80d6a3a3a5e5f70 schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 N881b9780b0dc41aca13870e8eacf1e00 schema:name dimensions_id
87 schema:value pub.1091501707
88 rdf:type schema:PropertyValue
89 Nb192e0f288e241a38f7ee299fcd00135 schema:volumeNumber 19
90 rdf:type schema:PublicationVolume
91 Nb35f2684f920474dad0532c12e5d6b50 rdf:first sg:person.01077063633.56
92 rdf:rest rdf:nil
93 Nb5708d34e78e4b348a155ac1736d7f83 schema:name doi
94 schema:value 10.1007/s11908-017-0588-3
95 rdf:type schema:PropertyValue
96 Nf804302418da4e299c257806eeeafd80 rdf:first sg:person.01122530351.85
97 rdf:rest N3f8c1d801d08431fb8059824df0714ac
98 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
99 schema:name Medical and Health Sciences
100 rdf:type schema:DefinedTerm
101 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
102 schema:name Clinical Sciences
103 rdf:type schema:DefinedTerm
104 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
105 schema:name Medical Microbiology
106 rdf:type schema:DefinedTerm
107 sg:journal.1021184 schema:issn 1523-3847
108 1534-3146
109 schema:name Current Infectious Disease Reports
110 schema:publisher Springer Nature
111 rdf:type schema:Periodical
112 sg:person.01077063633.56 schema:affiliation grid-institutes:grid.410511.0
113 schema:familyName Gallien
114 schema:givenName Sébastien
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077063633.56
116 rdf:type schema:Person
117 sg:person.01113507765.40 schema:affiliation grid-institutes:None
118 schema:familyName Flateau
119 schema:givenName Clara
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113507765.40
121 rdf:type schema:Person
122 sg:person.01122530351.85 schema:affiliation grid-institutes:grid.410511.0
123 schema:familyName Henn
124 schema:givenName Aurélia
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122530351.85
126 rdf:type schema:Person
127 sg:pub.10.1007/s10461-017-1788-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085215059
128 https://doi.org/10.1007/s10461-017-1788-4
129 rdf:type schema:CreativeWork
130 sg:pub.10.1186/s12879-015-0892-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047706498
131 https://doi.org/10.1186/s12879-015-0892-1
132 rdf:type schema:CreativeWork
133 grid-institutes:None schema:alternateName Service d’immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Creteil, France
134 schema:name Service d’immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Creteil, France
135 rdf:type schema:Organization
136 grid-institutes:grid.410511.0 schema:alternateName Faculté de médecine, Université Paris-Est Créteil, Créteil, France
137 schema:name Faculté de médecine, Université Paris-Est Créteil, Créteil, France
138 Service d’immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Creteil, France
139 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...